Home/Pipeline/ENT-3379

ENT-3379

Fragile X Syndrome

Phase 1Active

Key Facts

Indication

Fragile X Syndrome

Phase

Phase 1

Status

Active

Company

Enthorin Therapeutics

About Enthorin Therapeutics

Enthorin Therapeutics is a private, clinical-stage biotech based in Cambridge, USA, leveraging a circuit-based therapeutic approach for CNS disorders. The company's lead asset, ENT-3379 for Fragile X Syndrome, is being advanced through a significant partnership with Mirum Pharmaceuticals. Founded by seasoned drug developers and a leading clinical neuroscientist, Enthorin is positioned to address major gaps in the treatment of conditions like Fragile X, Autism Spectrum Disorders, and Parkinson's Disease.

View full company profile

Therapeutic Areas

Neurodevelopmental Disorders Neurodegenerative Diseases

Other Fragile X Syndrome Drugs

Drug	Company	Phase	Status
KER-0193	Kaerus Bioscience	Preclinical	Active
p70 S6 Kinase Inhibitor	Epigen Biosciences	Preclinical	Active
HLX-0206	Healx	AI Discovery	Active
AUT00206	Autifony Therapeutics	Clinical	Active
Fragile X Program	Sentinel Oncology	Preclinical	Active
Fragile X Syndrome Program	Purposeful	Discovery/Pre-clinical	Active
Fragile X Syndrome Trial	Science 37	Phase 3	Completed/Highlighted
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Phase 2	Completed
Fragile X Syndrome Test	Genomics BioSci & Tech	Clinical	Active
Xanamem (emestedastat)	Actinogen Medical	Phase 2	Active